Related Experiment Video
Updated: Jul 10, 2025

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
Published on: June 16, 2017
MLH1 Promoter Methylation Could Be the Second Hit in Lynch Syndrome Carcinogenesis
Ileana Wanda Carnevali1,2, Giulia Cini3, Laura Libera2,4
1UO Anatomia Patologica Ospedale di Circolo ASST-Settelaghi, 21100 Varese, Italy.
Abstract:
(1) Background: MLH1 hypermethylation is an epigenetic alteration in the tumorigenesis of colorectal cancer (CRC) and endometrial cancer (EC), causing gene silencing, and, as a consequence, microsatellite instability. Commonly, MLH1 hypermethylation is considered a somatic and sporadic event in cancer, and its detection is recognized as a useful tool to distinguish sporadic from inherited conditions (such as, Lynch syndrome (LS)). However, MLH1 hypermethylation has been described in rare cases of CRC and EC in LS patients. (2) Methods: A total of 61 cancers (31 CRCs, 27 ECs, 2 ovarian cancers, and 1 stomach cancer) from 56 patients referred to cancer genetic counselling were selected for loss of MLH1 protein expression and microsatellite instability. All cases were investigated for MLH1 promoter methylation and MLH1/PMS2 germline variants. (3) Results: Somatic MLH1 promoter hypermethylation was identified in 16.7% of CRC and in 40% of EC carriers of MLH1 germline pathogenic variants. In two families, primary and secondary MLH1 epimutations were demonstrated. (4) Conclusions: MLH1 hypermethylation should not be exclusively considered as a sporadic cancer mechanism, as a non-negligible number of LS-related cancers are MLH1 hypermethylated. Current flow charts for universal LS screening, which include MLH1 methylation, should be applied, paying attention to a patient's family and personal history.
Insights
MLH1 hypermethylation, often seen as sporadic, also occurs in Lynch syndrome cancers. This finding impacts colorectal and endometrial cancer screening protocols, requiring consideration of family history.
Area of Science:
- Oncology
- Epigenetics
- Cancer Genetics
Background:
- MLH1 hypermethylation is an epigenetic alteration linked to colorectal cancer (CRC) and endometrial cancer (EC) tumorigenesis, causing gene silencing and microsatellite instability.
- MLH1 hypermethylation is typically viewed as a sporadic event, aiding in distinguishing sporadic cancers from inherited conditions like Lynch syndrome (LS).
- However, rare instances of MLH1 hypermethylation have been documented in LS patients with CRC and EC.
Purpose of the Study:
- To investigate the occurrence and significance of MLH1 hypermethylation in cancers from patients undergoing genetic counseling.
- To determine if MLH1 hypermethylation is exclusively a sporadic event or if it also presents in Lynch syndrome-associated cancers.
Main Methods:
- Analyzed 61 cancers (31 CRCs, 27 ECs, 2 ovarian, 1 stomach) from 56 patients for MLH1 protein loss and microsatellite instability.
- Investigated MLH1 promoter methylation and MLH1/PMS2 germline variants in all selected cases.
Main Results:
- Somatic MLH1 promoter hypermethylation was detected in 16.7% of CRC and 40% of EC cases with MLH1 germline pathogenic variants.
- Primary and secondary MLH1 epimutations were identified in two families, indicating complex inheritance patterns.
Conclusions:
- MLH1 hypermethylation is not solely a sporadic cancer mechanism; a notable proportion of Lynch syndrome-related cancers exhibit MLH1 hypermethylation.
- Current universal Lynch syndrome screening protocols incorporating MLH1 methylation testing should be carefully applied, considering individual patient and family history.
Related Concept Videos
Epigenetic Regulation
Abnormal Proliferation
Non-LTR Retrotransposons
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...

